Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients

BACKGROUND: Letermovir (LTV) might be an alternative treatment to nephrotoxic foscarnet (FOS) in Ganciclovir (GCV) resistant cytomegalovirus (CMV) infection. However, its efficacy in controlling active CMV viremia is unclear, as it is only approved for CMV prophylaxis in hematopoietic stem‐cell tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Rho, Elena, Näf, Bettina, Müller, Thomas F, Wüthrich, Rudolf P, Schachter, Thomas, von Moos, Seraina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285377/
https://www.ncbi.nlm.nih.gov/pubmed/34181768
http://dx.doi.org/10.1111/ctr.14401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285377/
https://www.ncbi.nlm.nih.gov/pubmed/34181768
http://dx.doi.org/10.1111/ctr.14401

Ejemplares similares